Background: Hepatitis B virus (HBV) establishes lamivudine resistance via the resistance-causative rtM204V/I mutation and the replication-compensatory rtL180M mutation. However, both lamivudine-resistant viruses with and those without rtL180M can exist in clinical settings. To elucidate the differences between viruses with and those without rtL180M, we conducted full-length sequencing analysis of HBV derived from patients with type B chronic hepatitis showing lamivudine resistance.

Methods: The full-length HBV DNA sequences derived from 44 patients showing lamivudine resistance were determined by polymerase chain reaction direct sequencing. Viral replicative competence was examined by in vitro transfection analysis using various HBV-expressing plasmids.

Results: Throughout the HBV genome, a precore-defective A1896 mutation and a short deletion in the preS2 gene were detected more frequently in viruses without rtL180M than in those with it (64% vs. 17% [P < .005] and 50% vs. 10% [P < .01], respectively). In vitro transfection analysis revealed that the level of reduction in intracellular viral replication caused by the introduction of lamivudine resistance-associated mutations was lower in precore-defective and preS2-deleted viruses than in wild-type virus.

Conclusions: Both the precore-defective mutation and the preS2 deletion may play a supportive role in the replication of lamivudine-resistant HBV, which may be a reason for there being no need for the compensatory rtL180M mutation in lamivudine-resistant HBV possessing the precore and preS2 genomic changes.

Download full-text PDF

Source
http://dx.doi.org/10.1086/591941DOI Listing

Publication Analysis

Top Keywords

viruses rtl180m
12
supportive role
8
precore pres2
8
pres2 genomic
8
genomic changes
8
hepatitis virus
8
lamivudine resistance
8
rtl180m mutation
8
mutation lamivudine-resistant
8
derived patients
8

Similar Publications

Evaluation of genotype characteristics and drug resistance mutations in patients with chronic hepatitis B.

Sci Rep

November 2024

Department of Clinical Laboratory, Chongqing Qianjiang Central Hospital, Qianjiang Key Laboratory of Chongqing Qianjiang Central Hospital Laboratory Medicine, Chongqing University Qianjiang Hospital, No. 360 South Section, Zhengzhou Road, Qianjiang District, Chongqing, 409000, China.

Hepatitis B is one of the public health priorities worldwide, especially in the Southwest China. Our study aimed to investigate the relationship between genotypes and drug resistance mutations among HBV patients in Southwest China, with the objective of providing guidance for clinical antiviral treatment. A total of 4266 chronic hepatitis B (CHB) patients treated in the Qianjiang Hospital of Chongqing University were included in our study from 2014 to 2020.

View Article and Find Full Text PDF

Aim: Patients with chronic hepatitis B virus (HBV) infection experiencing viral breakthrough (BTH) or partial response (PR) during lamivudine (LAM) or entecavir hydrate (ETV) administration often took ETV plus tenofovir alafenamide fumarate (TAF) due to the emergence of a drug-resistance mutation. However, in patients lacking drug-resistance mutation against TAF, sufficient antiviral effects may be achievable with TAF monotherapy. We assessed the drug-resistance profile through nucleotide sequences of HBV pregenome RNA, and subsequently changed to TAF monotherapy from ETV plus TAF.

View Article and Find Full Text PDF

The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection.

J Virus Erad

September 2023

Department of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Background: The significance of hepatitis B virus (HBV) in cerebrospinal fluid (CSF) is unclear.

Methods: Synchronous serum and CSF samples were collected from 13 patients. HBV DNA, full-length genome, quasispecies, phylogenetic tree, compartmentalization and mutation of the reverse transcriptase (RT) region were performed based on PCR and sequencing methods.

View Article and Find Full Text PDF

Hepatitis B virus (HBV) antiviral Resistance-Associated Mutations (RAMs) in human immunodeficiency virus (HIV) coinfected patients undergoing highly active antiretroviral therapy (HAART) are complex and incompletely understood. We aimed to determine the prevalence of HBV coinfection, HBV genotypes, and RAMs in a cohort of people living with HIV (PLWH) in the northeastern region of Colombia. This cross-sectional study was carried out between February 2013 and February 2014.

View Article and Find Full Text PDF

[Analysis of characteristics of drug resistance gene mutation in HBV RT region of hepatitis B infected patients].

Zhonghua Yu Fang Yi Xue Za Zhi

June 2023

Department of Clinical Laboratory, the Fifth Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing 100039, China School of Medical Laboratory, Weifang Medical University, Weifang 261053, China Department of Laboratory Medicine, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350122, China.

This article investigated the clinical characteristics and distribution of drug resistance mutation sites in HBV RT region of hepatitis B infected patients. Retrospective analysis was made on 1 948 patients with HBV infection, who had been tested for NAs resistance mutation and had a medical history of NAs in the Laboratory Department of the Fifth Medical Center of the PLA General Hospital from January 2020 to December 2021. Basic clinical information and drug resistance related mutation information were recorded.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!